Element Biosciences AVITI¿ 24 sequencing and spati

The National Cancer Institute (NCI), Center for Cancer Research (CCR), is seeking to acquire an Element Biosciences AVITI24 Sequencing System for joint operation by the CCR Genomics Core and the CCR High-Throughput Imaging Facility (HiTIF). The system will enhance the shared research capabilities of the NCI. The acquisition is being processed as a sole source action, with Element Biosciences being the original equipment manufacturer (OEM) with the capability to provide the specific instruments and associated system compatibility necessary to support CCR’s mission requirement. • The system must be delivered within 4 weeks after contract award. • The contractor must provide a capability statement, which should not exceed five pages and must be submitted electronically. • The Government will consider all capabilities statements received by the specified deadline. • The acquisition is being processed in accordance with Revolutionary FAR Overhaul (RFO) 12.201-1.